$プライム・メディスン(PRME.US)$ NEWS Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
CEO Dr. Gottesdiener anticipates that Dr. Reine's extensive experience will significantly contribute to Prime Medicine's financing strategies and operational efficiency. Dr. Reine is enthusiastic about joining the company as it transitions to a clinical-stage venture.
プライム・メディスンに関するコメント
NEWS
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
まだコメントはありません